EIP Pharma's Series A Round

EIP Pharma raised a round of funding on January 17, 2017.

EIP Pharma is a private company that has licensed-in and is developing neflamapimod (previously code-named VX-745), a phase 2 clinical-stage oral investigational drug that inhibits the enzyme p38 MAP …

Articles about EIP Pharma's Series A Round: